25 May 2012

Expanding Cyprotex lines up deals 

25/08/2011 Robert Tyerman

Contract drug researcher Cyprotex (CRX) hopes to enter a major new area after lifting first-half revenues 43 per cent to £3.53 million. That is the message from chief executive officer Dr. Anthony Baxter, who describes the growth in the six months to June as a 'huge vindication' of the AIM-quoted company's £2.7 million shares-and-cash takeover last year of US toxicology specialist Apredica and other toxicology moves costing £500,000, although they have yet to benefit the bottom line.

In fact, Macclesfield-based Cyprotex, already a world leader in 'ADME', pre-clinical absorption, metabolism and excretion, saw first-half pre-tax profits drop from £50,500 to a barely visible £658, as costs associated with this expansion increased and the company lost its biggest single customer, which was taken over by another group. Baxter suggests 2012 should bring the profits pay-off on the Apredica and other deals, which have brought Cyprotex face to face with the big pharmaceutical groups as customers for its 'proprietary and unique' toxicology assays for their developing products.

He says 'a new area is coming up, as big as toxicology' as 'the next big thing' for the company, whose cash fell from £1 million to £535,000 betwen December and June, though he will not say more at this stage. Baxter, who argues current price-cutting competition in the sector should ease as weaker brehren go the wall, is clear Cyprotex would look at new acquisition opportunities, as long as they are 'small, profitable or near profitability and preferably on the West Coast of the USA or in Europe'.

However strongly vindicated, Cyprotex is still far from a stockmarket darling. Floated at 29p nine years ago, the shares, which have traded between 6.38p and 3.5p over the past year, now change hands at 3.88p, up 0.13p this morning, valuing the company at £8.7 million, and offering speculative recovery potential.          

 

Tags: AIM market, Apredica, Contract drug research, Dr. Anthony Baxter, Toxicology

Sector: Pharmaceuticals & Biotechnology

Companies: Cyprotex

Achieve impressive returns

Gain instant access to some of the best-performing and fastest growing companies in the small cap arena

Click here

Achieve impressive returns on the go

Gain instant access to some of the best-performing and fastest growing companies in the small cap arena. Sign up NOW!

Institutional Investors in AIM 2011 - New Report

This unique study analyses the shareholdings of companies listed on AIM, extracting trends including rankings of the value and number of their investments.
Please click here to order your copy of the report or call 0207 250 7056.

Coverage of AIM, techMARK and PLUS Markets

Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.

If you're interested in business tax updates visit our specialist tax guide website.

Latest small-cap and growth company news

Daily coverage of small-cap company stocks on London's junior markets AIM and PLUS, breaking news, stock research and latest share price information for investors. Full sector coverage with all the latest news on smaller listed companies, updated several times a day with financial reports, trading statements and links to further web resources.

Popular News

Latest News

Gulf starts at Sheikh Adi-2 25/05/2012

Iraq-focused oil explorer Gulf Keystone Petroleum (GKP) has begun drilling at the Sheikh Adi-2 well in the Sheikh Adi block.

Tags: Doing business in Iraq, Drilling on AIM, Oil on AIM

Sector: Oil & Gas Producers

Companies: Gulf Keystone Petroleum

Shell considers Cove 24/05/2012

Oil giant Shell is extending its offer period for Mozambique-focused Cove Energy (COV) after having its bid trumped by Thai government-owned PTT Exploration & Production.

Tags: Bid trumped, Doing business in Mozambique, Oil giants on AIM, Takeovers and bids

Sector: Oil & Gas Producers

Companies: Royal Dutch Shell 'A' , Cove Energy

Roxi reaches 1,360 metres 23/05/2012

Kazakhstan-focused Roxi Petroleum (RXP) has declared that its NK7 well in the Galaz aea has drilled to a depth of 1,360 metres.

Tags: AIM ventures, Doing business in Kazakhstan, Oil on AIM

Cluff Natural Resources joins AIM 22/05/2012

Steered by sector veteran Algy Cluff, North-Sea focused cash shell Cluff Natural Resources (CNR) has joined AIM.

Tags: Entrepreneurs on AIM, Gold mining, Oil and gas on AIM

Red Emperor exercises Shabeel 21/05/2012

Somalia-focused oil explorer Red Emperor Resources (RMP) has exercised its option to take part in the drilling of the Shabeel North well.

Tags: Business in the Puntland, Doing business in Somalia, Drilling for oil & gas, Oil on AIM

Sector: Oil & Gas Producers

Companies: Red Emperor Resources

Heritage happy in Iraq 18/05/2012

Oil concern Heritage Oil (HOIL) has reported its Miran West-3 well in Iraq could deliver 1,000 barrels per day of condensate.

Tags: Doing business in Iraq, Oil on the full list, Oil production, Target depth

Sector: Oil & Gas Producers

Companies: Heritage Oil

More News

Sectors